{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:33:33Z","timestamp":1793392413612,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s40263-016-0382-z","type":"journal-article","created":{"date-parts":[[2016,8,21]],"date-time":"2016-08-21T23:19:21Z","timestamp":1471821561000},"page":"1043-1054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"30","author":[{"given":"Kim S. J.","family":"Lao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M. C.","family":"Besag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,22]]},"reference":[{"key":"382_CR1","doi-asserted-by":"publisher","first-page":"g1173","DOI":"10.1136\/bmj.g1173","volume":"348","author":"E Kuipers","year":"2014","unstructured":"Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ. 2014;348:g1173. doi: 10.1136\/bmj.g1173 .","journal-title":"BMJ"},{"key":"382_CR2","doi-asserted-by":"publisher","unstructured":"Kendall T, Morriss R, Mayo-Wilson E, Marcus E, Guideline Development Group of the National Institute for H, Care E. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ. 2014;349:g5673. doi: 10.1136\/bmj.g5673 .","DOI":"10.1136\/bmj.g5673"},{"key":"382_CR3","unstructured":"Publication No. WO\/2009\/104739 Published on Aug. 27, Assigned to Mitsubishi Tanabe Pharma for Oral Administration Solid Preparation (Japanese Inventors). US Fed News Service, Including US State News. 3 September 2009."},{"issue":"2","key":"382_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1755-5949.2010.00222.x","volume":"17","author":"M Nord","year":"2011","unstructured":"Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011;17(2):97\u2013103. doi: 10.1111\/j.1755-5949.2010.00222.x .","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"382_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/pcn.12242","volume":"69","author":"I Kusumi","year":"2015","unstructured":"Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci. 2015;69(5):243\u201358. doi: 10.1111\/pcn.12242 .","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"382_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79\u2013104. doi: 10.1038\/sj.mp.4001556 .","journal-title":"Mol Psychiatry."},{"issue":"11","key":"382_CR7","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686\u201396. doi: 10.1176\/ajp.156.11.1686 .","journal-title":"Am J Psychiatry"},{"issue":"1","key":"382_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19\u201332. doi: 10.1016\/j.schres.2005.07.014 .","journal-title":"Schizophr Res"},{"issue":"1","key":"382_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","volume":"62","author":"DC Henderson","year":"2005","unstructured":"Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62(1):19\u201328. doi: 10.1001\/archpsyc.62.1.19 .","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"382_CR10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archpsyc.59.11.1021","volume":"59","author":"CE Koro","year":"2002","unstructured":"Koro CE, Fedder DO, L\u2019Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59(11):1021\u20136.","journal-title":"Arch Gen Psychiatry"},{"issue":"9468","key":"382_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415\u201328. doi: 10.1016\/S0140-6736(05)66378-7 .","journal-title":"Lancet"},{"issue":"12","key":"382_CR12","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323. doi: 10.1056\/NEJMoa051688 .","journal-title":"N Engl J Med"},{"key":"382_CR13","unstructured":"US Department of Health and Human Services; US Food and Drug Administration. FDA approves new drug to treat schizophrenia and bipolar disorder. Available at http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm463103.htm . Accessed 29 Dec 2015."},{"issue":"4","key":"382_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","volume":"35","author":"JM Kane","year":"2015","unstructured":"Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367\u201373. doi: 10.1097\/JCP.0000000000000346 .","journal-title":"J Clin Psychopharmacol"},{"key":"382_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000110","author":"S Durgam","year":"2015","unstructured":"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int Clin Psychopharmacol. 2015;. doi: 10.1097\/YIC.0000000000000110 .","journal-title":"Int Clin Psychopharmacol"},{"issue":"2\u20133","key":"382_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","volume":"152","author":"S Durgam","year":"2014","unstructured":"Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2\u20133):450\u20137. doi: 10.1016\/j.schres.2013.11.041 .","journal-title":"Schizophr Res"},{"issue":"12","key":"382_CR17","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","volume":"76","author":"S Durgam","year":"2015","unstructured":"Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574\u201382. doi: 10.4088\/JCP.15m09997 .","journal-title":"J Clin Psychiatry"},{"key":"382_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","volume":"174","author":"GS Sachs","year":"2015","unstructured":"Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296\u2013302. doi: 10.1016\/j.jad.2014.11.018 .","journal-title":"J Affect Disord"},{"issue":"1","key":"382_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bdi.12238","volume":"17","author":"S Durgam","year":"2015","unstructured":"Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63\u201375. doi: 10.1111\/bdi.12238 .","journal-title":"Bipolar Disord"},{"issue":"3","key":"382_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4088\/JCP.14m09081","volume":"76","author":"JR Calabrese","year":"2015","unstructured":"Calabrese JR, Keck PE Jr, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284\u201392. doi: 10.4088\/JCP.14m09081 .","journal-title":"J Clin Psychiatry"},{"key":"382_CR21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15020164","author":"S Durgam","year":"2015","unstructured":"Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Nemeth G, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2015;. doi: 10.1176\/appi.ajp.2015.15020164 .","journal-title":"Am J Psychiatry."},{"issue":"3","key":"382_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4088\/JCP.15m10070","volume":"77","author":"S Durgam","year":"2016","unstructured":"Durgam S, Earley W, Guo H, Li D, Nemeth G, Laszlovszky I, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(3):371\u20138. doi: 10.4088\/JCP.15m10070 .","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"382_CR23","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","volume":"59","author":"I Gyertyan","year":"2011","unstructured":"Gyertyan I, Kiss B, Saghy K, Laszy J, Szabo G, Szabados T, et al. Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochemist Int. 2011;59(6):925\u201335. doi: 10.1016\/j.neuint.2011.07.002 .","journal-title":"Neurochemist Int."},{"issue":"1","key":"382_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","volume":"333","author":"B Kiss","year":"2010","unstructured":"Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328\u201340. doi: 10.1124\/jpet.109.160432 .","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"382_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.schres.2015.06.027","volume":"168","author":"RR Girgis","year":"2015","unstructured":"Girgis RR, Xu X, Gil RB, Hackett E, Ojeil N, Lieberman JA, et al. Antipsychotic binding to the dopamine-3 receptor in humans: a PET study with [(11)C]-(+)-PHNO. Schizophr Res. 2015;168(1\u20132):373\u20136. doi: 10.1016\/j.schres.2015.06.027 .","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"382_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.schres.2011.05.005","volume":"131","author":"R Mizrahi","year":"2011","unstructured":"Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S, et al. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res. 2011;131(1\u20133):63\u20138. doi: 10.1016\/j.schres.2011.05.005 .","journal-title":"Schizophr Res"},{"issue":"6","key":"382_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/archgenpsychiatry.2009.43","volume":"66","author":"A Graff-Guerrero","year":"2009","unstructured":"Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, et al. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. Arch Gen Psychiatry. 2009;66(6):606\u201315. doi: 10.1001\/archgenpsychiatry.2009.43 .","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"382_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1017\/S0033291714001305","volume":"45","author":"A Yildiz","year":"2015","unstructured":"Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. 2015;45(2):299\u2013317. doi: 10.1017\/S0033291714001305 .","journal-title":"Psychol Med"},{"issue":"1","key":"382_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4088\/JCP.15m10192","volume":"77","author":"L Citrome","year":"2016","unstructured":"Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry. 2016;77(1):109\u201315. doi: 10.4088\/JCP.15m10192 .","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"382_CR30","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.euroneuro.2015.08.020","volume":"25","author":"E Vieta","year":"2015","unstructured":"Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S. Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II\/III trials. Eur Neuropsychopharmacol. 2015;25(11):1882\u201391. doi: 10.1016\/j.euroneuro.2015.08.020 .","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"382_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/npp.2010.192","volume":"36","author":"A Yildiz","year":"2011","unstructured":"Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36(2):375\u201389. doi: 10.1038\/npp.2010.192 .","journal-title":"Neuropsychopharmacology."},{"key":"382_CR32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.31887\/DCNS.2015.17.1\/bcuthbert","volume":"17","author":"S Zukin","year":"2015","unstructured":"Zukin S, Lu K, Ruth A, Debelle M, Durgam S, D\u2019Souza I. Categorical improvement across mania symptoms: pooled analyses of cariprazine phase II\/III trials. Bipolar Disord. 2015;17:89.","journal-title":"Bipolar Disord"},{"key":"382_CR33","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org . Accessed 15 June 2014."},{"key":"382_CR34","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136\/bmj.b2535 (Epub 2009\/07\/23).","journal-title":"BMJ."},{"key":"382_CR35","unstructured":"Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org . Accessed 8 Aug 2014."},{"key":"382_CR36","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. doi: 10.1136\/bmj.d4002 .","journal-title":"BMJ"},{"issue":"4","key":"382_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394. doi: 10.1016\/j.jclinepi.2010.04.026 .","journal-title":"J Clin Epidemiol"},{"key":"382_CR38","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University dbEP, Inc.). Available from gradepro.org."},{"issue":"1","key":"382_CR39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2307\/2530643","volume":"41","author":"S Greenland","year":"1985","unstructured":"Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41(1):55\u201368.","journal-title":"Biometrics."},{"issue":"4","key":"382_CR40","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719\u201348.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"382_CR41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials."},{"issue":"1","key":"382_CR42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101\u201329.","journal-title":"Biometrics."},{"issue":"7414","key":"382_CR43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. doi: 10.1136\/bmj.327.7414.557 (Epub 2003\/09\/06).","journal-title":"BMJ."},{"issue":"3","key":"382_CR44","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1751-5823.2009.00095_15.x","volume":"77","author":"A Rosenblad","year":"2009","unstructured":"Rosenblad A. Chapter 17: introduction to meta-analysis by Michael Borenstein, Larry V. Hedges, Julian PT Higgins, Hannah R. Rothstein. Int Stat Rev. 2009;77(3):478\u20139.","journal-title":"Int Stat Rev"},{"key":"382_CR45","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Wiley Online Library; 2008.","DOI":"10.1002\/9780470712184"},{"issue":"1","key":"382_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","volume":"172","author":"JP Higgins","year":"2009","unstructured":"Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A. 2009;172(1):137\u201359. doi: 10.1111\/j.1467-985X.2008.00552.x .","journal-title":"J R Stat Soc Ser A."},{"key":"382_CR47","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012."},{"key":"382_CR48","unstructured":"StatsToDo. Computer Program to Combine Means and Standard Deviations from Multiple Groups [cited Jan 2016]. Available from: https:\/\/www.statstodo.com\/ComMeans_Pgm.php ."},{"key":"382_CR49","unstructured":"US Food and Drug Administration. Full Prescribing information for VRAYLAR (cariprazine). 2015. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/204370lbl.pdf ."},{"key":"382_CR50","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1016\/j.eurpsy.2016.01.652","volume":"33","author":"G Nemeth","year":"2016","unstructured":"Nemeth G, Debelle M, Laszlovszky I, Szalai E, Szatmari B, Harsanyi J, et al. Monotherapy treatment with cariprazine for the treatment of predominant negative symptoms of patients with schizophrenia: a double-blind, active comparator-controlled trial. Eur Psychiatry. 2016;33:S256\u20137.","journal-title":"Eur Psychiatry."},{"issue":"9896","key":"382_CR51","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362. doi: 10.1016\/S0140-6736(13)60733-3 .","journal-title":"Lancet"},{"issue":"5","key":"382_CR52","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881111408461","volume":"26","author":"J Fruyt De","year":"2012","unstructured":"De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2012;26(5):603\u201317. doi: 10.1177\/0269881111408461 .","journal-title":"J Psychopharmacol."},{"issue":"2","key":"382_CR53","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1399-5618.2010.00798.x","volume":"12","author":"CU Correll","year":"2010","unstructured":"Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12(2):116\u201341. doi: 10.1111\/j.1399-5618.2010.00798.x .","journal-title":"Bipolar Disord"},{"issue":"1\u20132","key":"382_CR54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0920-9964(99)00191-7","volume":"45","author":"U Osby","year":"2000","unstructured":"Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45(1\u20132):21\u20138.","journal-title":"Schizophr Res."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0382-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0382-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0382-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T16:23:08Z","timestamp":1657124588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0382-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,22]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0382-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,22]]}}}